Will Maddox

Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead?

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.

KIT-targeting antibody biotech Jasper Therapeutics is being renewed via a merger with Nasdaq-listed Kira Pharmaceuticals—but not all of Kira's pipeline is coming along for the ride.

Biogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.

Bristol Myers Squibb may have been noticeable by its absence from the biotech buying spree of some of its U.S. Big Pharma peers this year.

Whether it's looming tariff threats or the rise of China as a innovation powerhouse, you need a truly global view to navigate today's biopharma industry.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.

Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly's Zepbound ads? And what are peptides?

Not content with navigating Rezdiffra's trajectory to blockbuster territory, Madrigal Pharmaceuticals has spent 2026 shopping for a range of drugs

Christopher Duntsch went to prison for killing his patients. Randall Kirby, a gifted surgeon, helped put him there. Then two of his own patients died, and everyone in the medical community fell silent.